MEDIRAD_en

6 Dec 2021 | Unclassified

MEDIRAD – Consequences of medical exposure to low dose radiation The evolution of medical science and the increasing pace of innovation and deployment of medical technology have led to a situation where the majority of artificial ionising radiation exposure to...

PINICAL-MRT_en

6 Dec 2021 | Unclassified

PINICAL-MRT : Clinical impact protocols in molecular radiotherapy Development of guidelines to translate knowledge on molecular radiotherapy into clinical practice Article 56 of the EC Directive 2013/59/EURATOM, detailing the requirements for individual dose planning...

CIEL_en

6 Dec 2021 | Unclassified

CIEL The CIEL project (Immune escape and innate immunity in lymphoma), builds on the important research work previously carried out by the team on the mechanisms of immune escape (IE) in malignant lymphomas, and in particular on the development of a multiparametric...

LUNG-RESIST_en

6 Dec 2021 | Unclassified

LUNG-RESIST Lung cancer is the major cause of cancer-related death in France and worldwide. In the past few years, patients with specific genetic alterations such as mutations in the EGFR gene (about 15% of lung adenocarcinomas, 45% in non-smokers), have benefited...

MELANICa_en

6 Dec 2021 | Unclassified

MELANICa Immunotherapies have revolutionised the therapeutic management of melanoma by increasing the immune response against this dreaded skin cancer. However, not all patients respond to immunotherapies and some relapse within two years following treatment...

Identification of immuno-escapement mechanisms by multiomics approaches.

3 Dec 2021 | NoLymIT research project, Unclassified

Pr Camille Laurent